Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2 Overexpressing Breast Cancer: A Phase I Dose-Escalation Study
Modi, S., Stopeck, A. T., Gordon, M. S., Mendelson, D., Solit, D. B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., Cropp, G. F., Johnson, R. G., Hannah, A. L., Hudis, C. A.Volume:
25
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2007.11.7960
Date:
December, 2007
File:
PDF, 2.11 MB
english, 2007